IBDEI20H ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32103,0)
 ;;=Z30.46^^126^1646^19
 ;;^UTILITY(U,$J,358.3,32103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32103,1,3,0)
 ;;=3^Surveillance Implantable Subdermal (Nexplanon),F/U
 ;;^UTILITY(U,$J,358.3,32103,1,4,0)
 ;;=4^Z30.46
 ;;^UTILITY(U,$J,358.3,32103,2)
 ;;=^5140424
 ;;^UTILITY(U,$J,358.3,32104,0)
 ;;=Z30.45^^126^1646^20
 ;;^UTILITY(U,$J,358.3,32104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32104,1,3,0)
 ;;=3^Surveillance Transdermal Patch Hormonal (Ortho Evra),F/U
 ;;^UTILITY(U,$J,358.3,32104,1,4,0)
 ;;=4^Z30.45
 ;;^UTILITY(U,$J,358.3,32104,2)
 ;;=^5140423
 ;;^UTILITY(U,$J,358.3,32105,0)
 ;;=Z30.44^^126^1646^21
 ;;^UTILITY(U,$J,358.3,32105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32105,1,3,0)
 ;;=3^Surveillance Vaginal Ring Hormonal (NuvaRing),F/U
 ;;^UTILITY(U,$J,358.3,32105,1,4,0)
 ;;=4^Z30.44
 ;;^UTILITY(U,$J,358.3,32105,2)
 ;;=^5140422
 ;;^UTILITY(U,$J,358.3,32106,0)
 ;;=Z30.016^^126^1646^22
 ;;^UTILITY(U,$J,358.3,32106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32106,1,3,0)
 ;;=3^Transdermal Patch Hormonal Device (Ortho Evra),Initial
 ;;^UTILITY(U,$J,358.3,32106,1,4,0)
 ;;=4^Z30.016
 ;;^UTILITY(U,$J,358.3,32106,2)
 ;;=^5140420
 ;;^UTILITY(U,$J,358.3,32107,0)
 ;;=Z30.015^^126^1646^24
 ;;^UTILITY(U,$J,358.3,32107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32107,1,3,0)
 ;;=3^Vaginal Ring Hormonal (NuvaRing),Initial
 ;;^UTILITY(U,$J,358.3,32107,1,4,0)
 ;;=4^Z30.015
 ;;^UTILITY(U,$J,358.3,32107,2)
 ;;=^5140419
 ;;^UTILITY(U,$J,358.3,32108,0)
 ;;=Z90.710^^126^1647^1
 ;;^UTILITY(U,$J,358.3,32108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32108,1,3,0)
 ;;=3^Acquired Absence of Cervix & Uterus
 ;;^UTILITY(U,$J,358.3,32108,1,4,0)
 ;;=4^Z90.710
 ;;^UTILITY(U,$J,358.3,32108,2)
 ;;=^5063591
 ;;^UTILITY(U,$J,358.3,32109,0)
 ;;=Z90.712^^126^1647^2
 ;;^UTILITY(U,$J,358.3,32109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32109,1,3,0)
 ;;=3^Acquired Absence of Cervix w/ Remaining Uterus
 ;;^UTILITY(U,$J,358.3,32109,1,4,0)
 ;;=4^Z90.712
 ;;^UTILITY(U,$J,358.3,32109,2)
 ;;=^5063593
 ;;^UTILITY(U,$J,358.3,32110,0)
 ;;=R87.619^^126^1647^3
 ;;^UTILITY(U,$J,358.3,32110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32110,1,3,0)
 ;;=3^Atypical Gland Cells,Undet Signif (AGCUS) Pap
 ;;^UTILITY(U,$J,358.3,32110,1,4,0)
 ;;=4^R87.619
 ;;^UTILITY(U,$J,358.3,32110,2)
 ;;=^5019676
 ;;^UTILITY(U,$J,358.3,32111,0)
 ;;=R87.611^^126^1647^4
 ;;^UTILITY(U,$J,358.3,32111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32111,1,3,0)
 ;;=3^Atypical Squam Cell,Not Excl Hi Grd Intrepith Lesn Cyto Smr Crvx
 ;;^UTILITY(U,$J,358.3,32111,1,4,0)
 ;;=4^R87.611
 ;;^UTILITY(U,$J,358.3,32111,2)
 ;;=^5019669
 ;;^UTILITY(U,$J,358.3,32112,0)
 ;;=D06.9^^126^1647^5
 ;;^UTILITY(U,$J,358.3,32112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32112,1,3,0)
 ;;=3^CA in Situ,Cervix
 ;;^UTILITY(U,$J,358.3,32112,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,32112,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,32113,0)
 ;;=D06.1^^126^1647^7
 ;;^UTILITY(U,$J,358.3,32113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32113,1,3,0)
 ;;=3^CA in Situ,Exocervix
 ;;^UTILITY(U,$J,358.3,32113,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,32113,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,32114,0)
 ;;=D06.0^^126^1647^6
 ;;^UTILITY(U,$J,358.3,32114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32114,1,3,0)
 ;;=3^CA in Situ,Endocervix
 ;;^UTILITY(U,$J,358.3,32114,1,4,0)
 ;;=4^D06.0
